2022 SMA Research & Clinical Care Meeting: What to Expect
Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.
Newborn Screening Awareness Month: Understanding the Impact of Newborn Screening for SMA
Advocacy organization Cure SMA provides insight on the importance of continuing to push for standardized newborn screening and how it can positively impact outcomes in SMA.
Mary Schroth, MD: Cure SMA’s Ongoing Advocacy Initiatives
The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.
Mary Schroth, MD: The Challenge of Early SMA Recognition
The chief medical officer at Cure SMA detailed the importance of having options for patients and how certain administration routes and schedules offer more personalized approaches, particularly for adult patients with SMA.
Mary Schroth, MD: The Impact of FDA Approvals on SMA Advocacy
The chief medical officer at Cure SMA detailed the importance of having various treatment options for patients, particularly for adults with SMA.
Mary Schroth, MD: Making Strides in Treating Spinal Muscular Atrophy
The chief medical officer at Cure SMA offers insight on the current SMA therapeutic landscape and what the organization is focused on going forward.
Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers
Advocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.
2 Clarke Drive Cranbury, NJ 08512